Several compounds were tested in cisplatin-resistant lung cancer PDO to restore chemosensitivity, such as YPN-005, which antagonizes CDK7, Solamargine, which blocks the hedgehog signaling pathway, and Halofuginone, which inhibits PI3K/AKT and MAPK signaling pathways [60–62]. This evidence concerns the gene PIK3CA and lung carcinoma.